IPOT — Isracann Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
Annual cashflow statement for Isracann Biosciences, fiscal year end - May 31st, CAD millions except per share, conversion factor applied.
C2018 May 31st | 2019 May 31st | 2020 May 31st | 2021 May 31st | 2022 May 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -7.47 | -9.9 | -23.9 | -25.1 | -4.69 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 3.77 | 5.3 | 13.4 | 20.9 | 2.2 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.19 | 0.87 | 0.113 | -0.063 | 0.694 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -2.93 | -2.94 | -10.4 | -4.23 | -1.75 |
| Capital Expenditures | -3.08 | 0 | -0.509 | -0.014 | 0 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -2.9 | -0.857 | -2.12 | 0.147 | -0.077 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -5.99 | -0.857 | -2.63 | 0.134 | -0.077 |
| Financing Cash Flow Items | 0 | 0 | 9.58 | -0.01 | 0.13 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 16.7 | 0 | 12.8 | 2.17 | 0.13 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 7.75 | -3.8 | -0.287 | -1.93 | -1.74 |